nach oben

Reactions Weekly

Erschienen in:

01.06.2017 | Case report

Natalizumab

Allergic reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

In an observational study, a girl [age at the reaction onset not stated] was described who developed allergic reaction during treatment with natalizumab [dosage, route and outcome not stated]. The girl was diagnosed with relapsing multiple sclerosis (MS) at the age of 16 years. She was started on natalizumab. However, natalizumab was discontinued only after one infusion due to allergic reaction. Later, she was switched to fingolimod followed by alemtuzumab. …

Willis M, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation 4: e320, No. 2, Mar 2017. Available from: URL: http://doi.org/10.1212/NXI.0000000000000320 - United Kingdom

Titel: Natalizumab
Allergic reaction: case report
Publikationsdatum: 01.06.2017
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-017-31680-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Natalizumab

Allergic reaction: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Cisplatin/doxorubicin/ifosfamide

Ipilimumab/nivolumab/pembrolizumab

Meropenem

Golimumab

Infliximab

Artemether/lumefantrine